Myasthenia gravis

Israeli researchers have investigated the risk of developing cancers other than thymoma in patients with autoimmune myasthenia gravis: data on 1,558 adults with myasthenia gravis were extracted from the Israeli Clalit health database, then compiled and compared with those of a control group; this group of patients had a higher rate of cancers (leukaemia or … [Read more]

French clinicians have examined the links between autoimmune myasthenia gravis and medications that are traditionally contraindicated (either formally or relatively) for this condition: The National Health Data System (SNDS) was used to conduct a study tracking potential complications associated with these medications over the 2013–2020 period; data from 14,459 people with autoimmune myasthenia gravis were … [Read more]

In order to study immune disorders in autoimmune myasthenia gravis, a recent study compared 86 patients with the disease and 90 hospitalized controls, matched for age and gender and assessed using the ICIQ-UI SF (urinary incontinence) and OABSS (overactive bladder) questionnaires. The prevalence of urinary incontinence was significantly higher in patients with autoimmune myasthenia gravis … [Read more]

Chinese clinicians report the case of a 73-year-old patient diagnosed with Lambert-Eaton myasthenic syndrome (LEMS) who underwent treatment with a latest-generation immunosuppressant: the patient met all the criteria necessary to confirm the diagnosis of LEMS, including the onset of motor disorders in the context of small cell lung cancer, a compatible electrophysiological study and positive … [Read more]

Chinese clinicians report encouraging results regarding the use of rituximab, an anti-CD20 monoclonal antibody, in forms of ocular myasthenia gravis: their pilot study involved 9 adult patients treated between 2023 and 2024 with a low dose of rituximab (200 mg), all of whom were seropositive for acetylcholine receptor (AChR) antibodies, the treatment led to a … [Read more]

Following the publication of initial success in 2024, a Chinese team has published the results of a multicentre phase I trial that evaluated three different doses of autologous anti-BCMA and anti-CD19 CAR-T cells preceded by lymphodepletion in 18 adults with refractory autoimmune myasthenia gravis: myasthenia had previously been resistant to IV immunoglobulins (67% of participants), … [Read more]

While there is still no consensus on the treatment of ocular myasthenia gravis, an Italian team conducted a retrospective study of 174 patients initially diagnosed with an ocular form of myasthenia gravis: 112 underwent thymectomy at the ocular stage of myasthenia gravis, 62 at the generalised stage; 29.3% had thymoma; the stable complete remission rate … [Read more]

An international consortium of clinicians reports the results of a phase III open-label trial designed to assess the benefit and tolerability of a monoclonal antibody, rozanolixizumab, administered by the patient either by manual pressure or via an infusion pump: 62 adults with generalised myasthenia gravis participated in the trial and were divided into two groups, … [Read more]

Taiwanese researchers conducted an exhaustive analysis of the literature on artificial intelligence (AI) tools in the context of predictive factors at certain stages of myasthenia gravis: a PRISMA-type approach was used to select 11 studies, which focused on prediction tools based on machine learning algorithms, with particular attention paid to admission to intensive care, length … [Read more]